Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Programmable cell-killing particle platform for targeted therapeutic delivery
Granza Bio is a biotechnology company developing a cell-targeted delivery platform based on supramolecular attack particles, naturally occurring structures used by cytotoxic T cells and natural killer cells to deliver lethal payloads with precision. The company is engineering programmable versions of these particles,…
GCP-accredited oncology molecular diagnostics for clinical trials and research
The Cancer Molecular Diagnostics Laboratory is an ISO 15189-accredited molecular diagnostics facility within the University of Cambridge Department of Oncology, jointly funded by CRUK and NIHR. Operating to GCP and GCLP standards, it provides next-generation sequencing, circulating tumour DNA analysis, liquid biopsy…
Engineered bacteria to remodel the tumour microenvironment
Neobe Therapeutics is a UK synthetic biology company developing programmable live biotherapeutics that colonise solid tumours and disrupt the local microenvironment to enable immune cell infiltration. The platform engineers tumour-colonising bacteria to break down stromal barriers that exclude immune cells, aiming to…
In vitro biology CRO for immunology and oncology drug discovery
BioMedha is a pre-clinical contract research organisation specialising in in vitro biology for early-stage drug discovery. The company provides assay development, target validation, compound screening, and mechanism of action studies across immunology, oncology, immuno-oncology, and inflammation therapeutic areas.…
Single-workflow sequencing technology capturing genetic and epigenetic data
biomodal is a Cambridge-based life sciences technology company developing multiomics sequencing solutions that simultaneously capture genetic and epigenetic information from a single DNA sample. Its multiomics platform detects the canonical four DNA bases alongside 5-methylcytosine and 5-hydroxymethylcytosine…
Plasma amino acid biomarkers for multi-cancer risk assessment
Proteotype Diagnostics develops blood tests to support earlier assessment of possible cancer. Its Enlighten test measures patterns of circulating amino acids in plasma and applies machine learning to estimate the likelihood of malignancy across several solid tumour types. It is designed to inform further clinical…
Antibody inhibitors of metzincin proteases for eye disease and cancer
Vasgen develops antibody therapeutics for eye disease and cancer, focusing on enzymes known as metzincin proteases. Its discovery platform uses monoclonal antibodies to inhibit these enzymes selectively, offering a different approach to targets that have proved challenging for conventional small-molecule medicines.…
Oncology biotech developing peptide therapeutics and diagnostics
ValiRx is a UK-listed biopharmaceutical company focused on the development of oncology therapeutics and companion diagnostics. The company selects and incubates novel drug candidates, including peptide-based compounds targeting prostate cancer, endometriosis, and other solid tumours, progressing them from preclinical…
Preclinical and clinical CRO specialising in biomarker services
Epistem is a contract research organisation providing preclinical and clinical research services to pharmaceutical and biotechnology companies. Its capabilities span in vivo and in vitro preclinical models across oncology, gastrointestinal disease, dermatology, and autoimmune indications, alongside GCLP-accredited…
AI-powered infrared diagnostic test for breast cancer recurrence risk
Digistain is a biotechnology company developing MHRA-cleared diagnostic technology for predicting breast cancer recurrence risk. The platform uses infrared spectrometry to generate spectroscopic signatures from tumour biopsy tissue, with AI analysis producing a personalised prognostic score indicating the likelihood…
Engineered T cell receptor therapies for solid tumour cancers
Adaptimmune is a clinical-stage biopharmaceutical company developing engineered T cell receptor therapies targeting solid tumours. The company's T-cell platform engineers T cell receptors with enhanced affinity for cancer-associated antigens, enabling immune recognition of tumour cells that evade conventional…
Viral vector platform for solid tumour immunotherapy
Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines. Lead…
Lentiviral vector yield enhancement via HDAC inhibitors and producer lines
Synthistat is a biotechnology company developing technologies to increase lentiviral vector production for cell and gene therapy manufacturing. Its work combines designed histone deacetylase (HDAC) inhibitors with approaches to modify HEK293 producer cells. The company has reported early laboratory results from…
Specialist CRO for rare disease drug development and commercialisation
TMC Pharma Services is a contract research organisation specialising in drug development support for rare and orphan diseases. The company serves small and mid-sized biotech and biopharma clients across the full development lifecycle, providing regulatory affairs, clinical development, pharmacovigilance, medical…
Targeting developmentally-silent oncogenic drivers for cancer therapy
Awen Oncology is a Welsh oncology biotechnology company developing first-in-class therapeutics that target cancer-specific proteins derived from developmental genes that are dormant in healthy adult tissue but aberrantly reactivated in tumour cells. The company's platform integrates high-throughput cell and molecular…
Non-invasive oral cancer screening using genomics and cell-free DNA
Wisdom Bioscience is a biotechnology company developing a non-invasive oral cancer screening platform that integrates next-generation sequencing and cell-free DNA analysis with saliva-based sample collection. The platform is designed to enable early detection of oral cancer through routine dental appointments,…
Programmable gene control platform for advanced cell therapies
Laverock Therapeutics is a biotechnology company developing a programmable gene control platform for the creation of disease-responsive advanced therapies. The platform uses recoded microRNAs to deliver tunable, stable and multiplexed gene silencing within cell therapies, enabling enhanced precision and improved…
AI-powered cancer biomarker profiling from tissue images
Panakeia is an AI diagnostics company developing software that predicts molecular biomarker status directly from standard H&E-stained tissue images. Its CE-marked and UKCA-certified breast cancer product reports ER, PR, and HER2 status in minutes, reducing the need for conventional laboratory testing. The platform…
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment. Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on…
Full-service CRO and pharmacovigilance services for biopharma
Ergomed is a global contract research organisation providing clinical development, pharmacovigilance, and regulatory compliance services to the pharmaceutical and biotechnology industries. Operating across more than 100 countries, the group manages Phase I to IV clinical trials with particular depth in oncology and…